{
    "clinical_study": {
        "@rank": "132946", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive daily oral 744 (30 mg tablets) for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of 800 mg of 744 LA at three time points at 12 week intervals as: Week 5, Week 17, and Week 29"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive daily oral matching placebo for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of saline at three time points at 12 week intervals as: Week 5, Week 17, and Week 29"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a Phase IIa, randomized, multi-site, two-arm, double-blinded study to evaluate\n      the safety, tolerability, and acceptability of GSK1265744 long acting injectable formulation\n      (744 LA) in adult male subjects.  To evaluate the safety and tolerability of the injectable\n      agent, 744 LA (800 milligrams (mg) dose administered at three time points at 12 week\n      intervals) through Week 41 in HIV-uninfected men.  Eligible participants will be randomized\n      in a 5:1 ratio to receive 744 LA or matching placebo.  Participants will receive daily oral\n      744 (30 mg tablets) or matching placebo for 4 weeks during the Oral Phase of the study,\n      followed by a one week washout period.  Following safety lab assessments from the Oral\n      Phase, participants will enter the Injection Phase and receive Intramuscular (IM) injections\n      of 744 LA or placebo at three time points at 12 week intervals.  IM injections will consist\n      of 800 mg of 744 or a matching control"
        }, 
        "brief_title": "Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infection, Human Immunodeficiency Virus", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-reactive HIV test at screening or enrollment.\n\n          -  Males 18 to 65 years old at the time of signing the informed consent.\n\n          -  At risk of acquiring HIV, defined as having at least one casual sex partner in the\n             past 24 months.\n\n          -  Healthy as determined by a responsible and experienced physician, based on a medical\n             evaluation including medical history, physical examination, laboratory tests and\n             cardiac monitoring at the time of screening.\n\n          -  If participating in sexual activity with a female of child-bearing potential, men\n             must agree to use condoms. Subjects who are sexual partners of females with child\n             bearing potential must also agree to practice an acceptable method of contraception\n             for the duration of the study, such as double barrier (male condom/spermicide, male\n             condom/diaphragm) or female partner use of hormonal contraception, intrauterine\n             device (IUD) or other method with published data showing that the lowest expected\n             failure rate for that is less than 1% per year.  All subjects participating in the\n             study must be counseled on safer sexual practices including the use of effective\n             barrier methods to minimize risk of HIV transmission.\n\n          -  Capable of giving written informed consent, which includes compliance with the\n             requirements and restrictions listed in the consent form.\n\n          -  Willing to undergo all required study procedures\n\n        Exclusion Criteria:\n\n          -  One or more reactive HIV test results at screening or enrollment, even if HIV\n             infection is not confirmed. Negative HIV Ribonucleic acid (RNA) must also be\n             documented at screening.\n\n          -  Assessed by the Investigator of Record or designee as being at \"high risk\" for HIV\n             infection. This may include one or more of the following:\n\n        The negative partner in an HIV serodiscordant couple Men who exchange sex for goods or\n        money Men who have engaged in unprotected receptive anal intercourse within the past 6\n        months Men who have had greater than 3 sexual partners within the past 3 months Men who\n        have had a sexually transmitted disease within the past 6 months Any other behavior\n        assessed by the investigator as \"high risk\"\n\n          -  Co-enrollment in any other HIV interventional research study (provided by self-report\n             or other available documentation) or prior enrollment and receipt of the active arm\n             (i.e., NOT a placebo) of a HIV vaccine trial (provided by available documentation).\n\n          -  Use of antiretroviral (ARV) therapy (e.g., for Post exposure prophylaxis (PEP) or Pre\n             exposure prophylaxis (PrEP) in the past 30 days, five half-lives, or twice the\n             duration of the biological effect of the applied treatment (whichever is longer)\n             prior to study enrollment.\n\n          -  Current or chronic history of liver disease, or known hepatic or biliary\n             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n\n          -  History of drug or alcohol consumption that in the opinion of the Principal\n             Investigator will interfere with study participation.\n\n          -  History of sensitivity to any of the study medications, or components thereof or a\n             history of drug or other allergy that, in the opinion of the investigator or Medical\n             Monitor, contraindicates their participation.\n\n          -  Any of the following laboratory values during the screening period. Positive\n             Hepatitis C antibody result Positive Hepatitis B surface antigen (HBsAg) Hemoglobin\n             less than 11 gram (g)/deci liter (dL) Absolute neutrophil count less than 750\n             cells/mm^3 Platelet count less than or equal to 100,000/mm^3 Presence of a\n             coagulopathy as defined by an INR greater than 1.5 or a PTT greater than 45sec\n             Calculated creatinine clearance less than 70 mL/minute using the Cockcroft-Gault\n             equation A single repeat test is allowed during the Screening period to verify a\n             result, with the exception of HIV tests.\n\n          -  Subjects with an alanine aminotransferase (ALT), alkaline phosphatase (ALP) or\n             bilirubin greater than or equal to1.5xULN (isolated bilirubin greater than 1.5xULN is\n             acceptable if bilirubin is fractionated and direct bilirubin less than 35%).\n\n          -  History of the following cardiac diseases: myocardial infarction, congestive heart\n             failure, documented hypertrophic cardiomyopathy, sustained ventricular tachycardia.\n\n          -  The subject's systolic blood pressure is outside the range of 90-160mmHg, or\n             diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside\n             the range of 45-100 beats per minute (bpm).\n\n          -  Exclusion criteria for screening (ECG (a single repeat is allowed for eligibility\n             determination) for Male Subjects:\n\n        Heart rate (A heart rate from 100 to 110 bpm can be rechecked within 30 minutes to verify\n        eligibility)-less than 45 and greater than 100 bpm.\n\n        QRS duration-greater than 120 msec. QTc interval (B or F)-greater than 450 msec. Evidence\n        of previous myocardial infarction (does not include ST segment changes associated with\n        repolarization).\n\n        Any conduction abnormality (including but not specific to left or right complete bundle\n        branch block, AV block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome).\n\n        Sinus Pauses greater than 3 seconds. Any significant arrhythmia which, in the opinion of\n        the principal investigator and medical monitor, will interfere with the safety for the\n        individual subject.\n\n        Non-sustained or sustained ventricular tachycardia (greater than or equal to 3 consecutive\n        ventricular ectopic beats).\n\n          -  Ongoing intravenous drug use - episodic use or any use in the past 90 days is\n             exclusionary (as assessed by the study investigator).\n\n          -  The subject has a tattoo or other dermatological condition overlying the gluteus\n             region which may interfere with interpretation of ISRs.\n\n          -  Use of high dose aspirin or any other anticoagulant or antiplatelet medication that\n             would interfere with the ability to receive intramuscular injections.\n\n          -  Active skin disease or disorder (i.e., infection, inflammation, dermatitis, eczema,\n             drug rash, psoriasis, urticaria).  Mild cases of localized acne or folliculitis or\n             other mild skin condition may not be exclusionary at the discretion of the\n             Investigator of Record or Medical Monitor)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076178", 
            "org_study_id": "201120"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "White to almost white oval shaped film coated 30 mg tablets for oral administration", 
                "intervention_name": "744 Tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1", 
                "description": "Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection", 
                "intervention_name": "744 LA Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "Microcrystalline cellulose, Opadry film-coating, white OY-S-28876", 
                "intervention_name": "Placebo Tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "Sterile saline 0.9% Sodium Chloride Injection", 
                "intervention_name": "Placebo Injection", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Integrase Inhibitors", 
                "Integrase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pre-Exposure Prophylaxis", 
            "HIV integrase", 
            "Intramuscular Injection", 
            "GSK1265744"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20009"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30339"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Fe", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87505"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Newport News", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23606"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "ViiV Healthcare", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the safety and tolerability of the injectable agent, 744 LA (800 mg dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men as assessed by adverse events", 
                "measure": "Safety and Tolerability as assessed by adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 41 (Final visit)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of the injectable agent, 744 LA (800 mg dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men as assessed by concurrent medication required", 
                "measure": "Safety and Tolerability as assessed by concurrent medication required", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 41 (Final visit)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of the injectable agent, 744 LA (800 mg dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men as assessed by clinical laboratory tests (Hematology/Chemistry testing and Urinalysis)", 
                "measure": "Safety and Tolerability as assessed by clinical laboratory tests", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 41"
            }, 
            {
                "description": "To evaluate the safety and tolerability of the injectable agent, 744 LA (800 mg dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men as assessed by ECG", 
                "measure": "Safety and Tolerability as assessed by Electrocardiogram (ECG)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 41"
            }, 
            {
                "description": "To evaluate the safety and tolerability of the injectable agent, 744 LA (800 mg dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men as assessed by vital signs assessments", 
                "measure": "Safety and Tolerability as assessed by vital signs assessments", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 41"
            }, 
            {
                "description": "To evaluate the safety and tolerability of the injectable agent, 744 LA (800 mg dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men as assessed by and injection site reactions (ISRs)", 
                "measure": "Safety and Tolerability as assessed by injection site reactions (ISRs)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 41 (Final visit)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076178"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following pharmacokinetic parameters were evaluated following each IM injection of 744 LA through 41 weeks. For each 12-week dosing interval, parameters include: Individual plasma PK parameters for each injection interval will be determined, including:  area under the plasma concentration time curve over the dosing interval (AUC(0-tau)), maximum observed concentration (Cmax), time to maximum observed concentration (tmax), concentration at the end of the dosing interval (Ctau), and apparent terminal phase half-life for LA administration (t\u00bd) and  lambda z as a measure of absorption rate constant (lambda   z) if data allow", 
                "measure": "Plasma pharmacokinetic profile for 744", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 41"
            }, 
            {
                "description": "The following pharmacokinetic parameters following each IM injection of 744 LA through 41 weeks. AUC(0-tau), Ctau, Cmax, t1/2, and lambda z) by age, race, weight, BMI and ethnicity", 
                "measure": "744 PK parameters as assessed by patient demographics (age, race, weight, BMI, and ethnicity)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 41"
            }, 
            {
                "description": "To evaluate the safety and tolerability of oral 744 in HIV-uninfected men as assessed by adverse events, clinical laboratory tests (Hematology/Chemistry testing and Urinalysis) and concurrent medication required", 
                "measure": "Safety and tolerability of oral 744", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 4"
            }, 
            {
                "description": "Acceptability of 744 LA injections was assessed by incidence and severity of ISRs and ISR symptom score", 
                "measure": "Acceptability of 744 LA injections", 
                "safety_issue": "No", 
                "time_frame": "Week 5 to Week 41"
            }, 
            {
                "description": "Pearson's correlations between PK parameters and safety parameters (occurrence of AEs, maximum intensity of AE per subject, and clinical laboratory parameters of special interest) may be presented. Logistic regression may be used to examine correlation between PK parameters and presence or absence of AEs of special interest from selected system organ class", 
                "measure": "Statistical evaluation for concentration-effect relationships for various safety parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 81"
            }
        ], 
        "source": "ViiV Healthcare", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "ViiV Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}